Dermorphin is a naturally occurring heptapeptide, Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, first isolated from the skin of the South American frog Phyllomedusa sauvagei. It is a highly selective agonist of the μ-opioid receptor and was one of the first vertebrate peptides found to contain a D-amino acid. In the laboratory it is studied as a reference ligand for μ-opioid receptor binding and signalling, as a model of D-amino acid-containing peptides, and as a template in structure-activity work. This article covers its structure, mechanism, published research, applications and the analytical and handling requirements that determine data quality.
What is dermorphin?
Dermorphin is a linear heptapeptide with an amidated C-terminus. Its formula is C40H50N8O10, and its molecular weight is about 802.9 Da. The sequence begins with tyrosine, followed by D-alanine at position 2, then phenylalanine, glycine, tyrosine, proline and serine amide. The N-terminal Tyr-D-Ala-Phe motif resembles the opening of the enkephalins, but the D-alanine at position 2 and the amidated C-terminus distinguish it from the mammalian opioid peptides.
The discovery came from the laboratory of Vittorio Erspamer, who spent decades characterising bioactive peptides in amphibian skin. Montecucchi and colleagues reported in the International Journal of Peptide and Protein Research in 1981 that methanol extracts of P. sauvagei skin contained a heptapeptide with very potent opiate-like activity. They determined its sequence and noted that it was a surprising example of a vertebrate peptide containing a D-amino acid residue. The name combines “derm”, for skin, with the “-orphin” ending of the morphine-like peptides. Related peptides from Phyllomedusa bicolor, including further dermorphins and the δ-selective deltorphins, were characterised later.
The D-alanine has practical consequences. Peptidases are stereospecific, so a D-residue near the N-terminus protects against aminopeptidase cleavage and prolongs stability in biological media. It also shapes the conformation of the N-terminal segment, which is required for receptor recognition. Richter, Egger and Kreil reported in Science in 1987 that the D-alanine is not encoded directly but arises after translation, when an L-alanine in the precursor is converted to the D-form, a finding that explained how a ribosomally made peptide could contain a D-residue.
Mechanism of action
Dermorphin acts at the μ-opioid receptor (MOR), a class A G protein-coupled receptor encoded by the OPRM1 gene. In binding studies it shows high affinity and marked selectivity for μ over δ and κ receptors, which is why it has been used as a μ-selective reference ligand since its discovery. The N-terminal tyrosine is essential: its protonated amine and phenolic hydroxyl occupy the orthosteric pocket in the same general way as the corresponding groups of morphine and the enkephalins, and the second aromatic residue, phenylalanine, extends into a hydrophobic region of the receptor.
The receptor couples to inhibitory G proteins of the Gi/o family. Activation inhibits adenylyl cyclase and lowers cyclic AMP, opens G protein-gated inwardly rectifying potassium (GIRK) channels, and suppresses voltage-gated calcium channels, which together reduce neuronal excitability and neurotransmitter release. The activated receptor is also phosphorylated by G protein-coupled receptor kinases and recruits β-arrestins, which mediate desensitisation and internalisation. Researchers often use dermorphin to compare G protein and arrestin signalling when characterising biased agonism at the receptor.
Structural biology has clarified the binding site. High-resolution structures of the μ-opioid receptor, first with an antagonist and later with an agonist and G protein bound, show the deep ligand pocket that accommodates the tyrosine side chain and the surrounding transmembrane residues that determine selectivity. Readers should note that these structures were solved with other ligands, so the dermorphin-bound conformation is inferred from them and from structure-activity data. Because the peptide is a potent receptor agonist, in-vitro concentration ranges are typically low, and careful dilution and verification of stock concentration are essential for reproducible dose-response curves.
What the research shows
Four bodies of published work frame the field.
The first is the isolation and sequencing. Montecucchi and colleagues, in the 1981 paper noted above, purified the heptapeptide from methanol extracts of P. sauvagei skin and determined that its sequence is H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2. The study established both the structure and the presence of a D-amino acid in a vertebrate peptide.
The second is the original pharmacology. Broccardo and colleagues reported in the British Journal of Pharmacology in 1981 that dermorphin and related peptides were potent opioid agonists in classical isolated-tissue bioassays, including the guinea-pig ileum and mouse vas deferens, and in rodent behavioural models, with potency well above that of morphine. The paper introduced the peptides as a new class of opioids from amphibian skin and set the pharmacological framework used in later studies.
The third is the biosynthesis. Richter, Egger and Kreil’s 1987 Science paper, described above, showed through cDNA analysis of frog skin that the precursor encodes L-alanine at the relevant position, which implies post-translational epimerisation to D-alanine. This work remains the standard reference for D-amino acid formation in animal peptides.
The fourth is the study of receptor subtypes. A 1992 report in PNAS described three naturally occurring dermorphin-related peptides from Phyllomedusa bicolor, their carboxyl-terminal amides and substituted analogues, determined their binding profiles at opioid receptors, and found that they activated two μ-receptor subtypes that modulated antinociception and catalepsy in the rat. The open-access text is available through PubMed Central. A broader historical account of the discovery and later research is given in an open-access review in PubMed Central.
These studies come from a small number of closely connected groups, and the in-vivo work was conducted under the animal-research rules of the time, so readers should consult the original methods and apply current ethical and licensing requirements before designing any animal experiment.
Research applications
The most common use is receptor pharmacology. In competition binding assays, dermorphin and its analogues are used to define μ-receptor affinity and selectivity, and in functional assays the peptide serves as an agonist reference in GTPγS binding, cAMP inhibition, GIRK channel and β-arrestin recruitment readouts in cells expressing the recombinant receptor. Comparing it with enkephalin analogues and with morphine helps characterise partial and full agonism.
Classical bioassays form a second area. Isolated tissue preparations such as guinea-pig ileum and mouse vas deferens, in which opioid agonists inhibit electrically evoked contractions, have been used for decades to rank opioid potency, and dermorphin was characterised in them from the outset. Structure-activity chemistry is a third. The peptide is a template for analogues in which substitutions at position 1, the D-residue at position 2 or the C-terminal residues are varied to alter selectivity, stability and receptor signalling, and tetrapeptide analogues described in the literature include those that later fed into the design of other mitochondria-targeted and opioid-active peptides.
Analytical chemistry is a fourth area. Anti-doping and equine-racing laboratories have reported LC-MS/MS methods for detecting the peptide in biological samples, so authenticated material serves as a reference standard for method validation. Biosynthesis and peptide chemistry research provides a fifth: the peptide is a standard example in studies of peptide epimerases and of the stability of D-amino acid-containing sequences.
Because it is a potent opioid agonist, laboratories should handle it under a documented risk assessment, restrict access to authorised staff, and confirm with their institution whether specific licensing or storage rules apply.
Purity, storage and handling
Verification begins with reversed-phase HPLC, monitored at 214 nm for the peptide bond and at about 275 to 280 nm for the two tyrosine residues, with purity commonly specified at 98% or above. Identity should be confirmed by mass spectrometry, with the monoisotopic [M+H]⁺ ion expected at about m/z 803.4. The stereochemistry needs special attention. The activity of dermorphin depends on the D-configuration at position 2, and the diastereomer containing L-alanine is reported to be much less active, so a method able to resolve the two, or a chiral amino acid analysis, is worth requesting for quantitative work. Net peptide content is a separate figure, since the vial also holds counter-ions and water.
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing Dermorphin should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and anyone comparing the best peptides supplier uk options can apply the same documentation requirements to any vendor.
A batch-specific certificate matters because impurity profiles differ between synthesis runs. Deletion sequences, racemised residues and incompletely deprotected tyrosine can appear in a given batch, and only the method conditions, batch number and test date show that the stated purity applies to the vial in hand. The salt form, usually acetate or trifluoroacetate, should be stated, since residual trifluoroacetate can interfere with cell-based signalling assays.
Lyophilised peptide is generally stored at -20°C, sealed and desiccated, and brought to room temperature before opening to prevent condensation. Short exposure to ambient temperature in transit is normally tolerated by dry powder. In solution the peptide lacks methionine, cysteine and tryptophan, so the usual oxidation routes are limited, but tyrosine can oxidise slowly, and hydrolysis and adsorption to plastic can reduce the effective concentration at low levels. Stock solutions are therefore normally kept at 2-8°C for short periods and divided into single-use aliquots to avoid repeated freeze-thaw cycles, with low-binding tubes preferred for dilute working solutions. Exact stability windows depend on buffer, pH and concentration, so they should be taken from supplier data and confirmed in-house for critical assays.
Light sensitivity is modest. The two tyrosine residues can undergo photo-oxidation on prolonged exposure to ultraviolet light, so amber vials or dark storage are advisable. Standard COSHH assessment and institutional waste procedures apply, and records of use are good practice for a potent receptor agonist.
Frequently asked questions
What is the sequence and molecular weight of dermorphin?
Dermorphin is the heptapeptide Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, with the formula C40H50N8O10 and a molecular weight of about 802.9 Da for the free peptide. The supplied powder weighs more because of counter-ions, so the salt form and net peptide content should be stated on the certificate.
Why does dermorphin contain D-alanine?
The D-alanine at position 2 arises after translation, when an L-alanine in the precursor is converted to the D-form in frog skin. The D-residue protects the peptide from aminopeptidases and shapes the N-terminal conformation needed for μ-opioid receptor binding, so stereochemical purity matters for any batch.
Which receptor does dermorphin act on?
Dermorphin is a highly selective agonist of the μ-opioid receptor, a Gi/o-coupled receptor. Activation lowers cyclic AMP, opens GIRK channels and recruits β-arrestins. In binding studies it shows much higher affinity for μ than for δ or κ receptors, which is why it is used as a μ-selective reference ligand.
How should lyophilised dermorphin be stored?
Lyophilised dermorphin is generally stored at -20°C in a sealed, desiccated container protected from light, and warmed to room temperature before opening. Reconstituted solutions are usually kept at 2-8°C for short periods as single-use aliquots, with stability limits confirmed from batch documentation.
Dermorphin is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and it must not be administered to people or animals.